DUBAI — A motor-free soft exosuit that assists walking and sit-to-stand transitions in older adults, detailed in a new study published in Nature, is drawing attention from UAE healthcare technology investors and rehabilitation providers weighing lighter-weight alternatives to motorized exoskeletons already piloted in Abu Dhabi and Dubai clinics.
The device, developed by researchers building on prior IEEE Spectrum-reported work, uses elastic textile components and mechanical energy storage rather than electric motors to reduce the effort required for standing up and walking. Early trials reported meaningful reductions in muscle activation and metabolic cost among elderly test subjects, positioning the suit as a low-cost, low-maintenance option compared with battery-powered rigid exoskeletons that require charging infrastructure and higher upfront capital.
Relevance to UAE Healthcare and Ageing Population Strategy
The UAE has made elderly care and rehabilitation technology a policy priority, with Abu Dhabi’s Department of Health and Dubai Health Authority both funding pilots in assistive robotics as part of broader healthcare-innovation and Emiratisation-of-care initiatives. A motor-free device lowers barriers to adoption in home-care settings, where power reliability, device servicing and trained technical staff are constraints outside major hospital networks. For UAE-based medtech distributors, a soft, motor-free exosuit represents a simpler regulatory and import pathway through the Ministry of Health and Prevention compared with powered medical robotics, potentially shortening time-to-market for regional deployment.
Investment and Manufacturing Signals for GCC Founders
Gulf sovereign wealth funds, including Mubadala and ADQ, have backed wearable robotics and healthtech startups as part of diversification into life sciences. A motor-free design suggests lower component costs and simpler supply chains, an attractive proposition for regional manufacturers exploring assembly or licensing deals rather than importing finished units from the US, Japan or South Korea. Founders in Dubai’s health-tech cluster and free zones such as Dubai Science Park may find licensing opportunities to localize production, aligning with the UAE’s push toward in-country manufacturing of medical devices under its industrial strategy. Analysts note that as the technology moves from lab validation toward commercialization, regional distribution partnerships are likely to emerge within 18 to 24 months.
